RxDoctor Payments Data

Traci Turner, MD

Cardiovascular Disease · Greensboro, NCNPI 1780784983

Payments from drug & device makers

$2,879in general payments, 2019–2025

Across 180 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$790
  • Novartis$427
  • Abiomed$243
  • Boehringer Ingelheim$209
  • Johnson & Johnson$173
  • Pfizer$144
  • plus $893 from 19 others

What the payments were for

  • Food & beverage$2,85699%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,879 in reported general payments places this provider in the 50th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$77,168
Medicare patients
878
Services billed
1,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban548$526,815
Repatha SureclickEvolocumab284$264,843
XareltoRivaroxaban158$176,295
EntrestoSacubitril/Valsartan69$98,784
JardianceEmpagliflozin49$53,569
FarxigaDapagliflozin Propanediol43$40,987
NexlizetBempedoic Acid/Ezetimibe42$30,854
Praluent PenAlirocumab37$30,411
VascepaIcosapent Ethyl50$29,986
BrilintaTicagrelor24$15,033
NexletolBempedoic Acid16$9,553
Icosapent Ethyl17$9,376
Metoprolol Succinate603$8,044
Ezetimibe387$6,892
CorlanorIvabradine Hcl13$6,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$144$526,815548 claims
Johnson & JohnsonXarelto$173$176,295158 claims
NovartisEntresto$427$98,78469 claims
AstraZenecaFarxiga, Brilinta$38$56,02067 claims
Boehringer IngelheimJardiance$209$53,56949 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$11$40,40758 claims
AmgenCorlanor$790$6,62713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →